Rapid degranulation of NK cells following activation by HIV-specific antibodies

Journal of Immunology

Volumn 182, Issue 2, 2009, Pages 1202-1210

  Chung, Amy W ^a   Rollman, Erik ^a   Center, Rob J ^a   Kent, Stephen J ^a,b,c   Stratov, Ivan ^a,b,c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GAMMA INTERFERON; GRANZYME B; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; 5 (6) CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; 5-(6)-CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CYTOKINE; DIAGNOSTIC AGENT; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; SUCCINIMIDE DERIVATIVE; VIRUS ENVELOPE PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; CELL ACTIVATION; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEGRANULATION; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOSYNTHESIS; BLOOD; CELL LINE; CHEMISTRY; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INTRACELLULAR FLUID; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; VIROLOGY;

ADULT; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DEGRANULATION; CELL LINE, TRANSFORMED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FLUORESCEINS; FLUORESCENT DYES; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; INTRACELLULAR FLUID; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; SUCCINIMIDES;

EID: 60549104848     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.2.1202     Document Type: Article

References (32)

1. Goulder, P. J., and D. I. Watkins. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8: 619-630.
2. Watkins, D. I., D. R. Burton, E. G. Kallas, J. P. Moore, and W. C. Koff. 2008. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14: 617-621.
3. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, and K. Choopanya. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194: 1661-1671.
4. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
5. Baum, L. L., K. J. Cassutt, K. Knigge, R. Khattri, J. Margolick, C. Rinaldo, C. A. Kleeberger, P. Nishanian, D. R. Henrard, and J. Phair. 1996. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157: 2168-2173.
6. Rook, A. H., H. C. Lane, T. Folks, S. McCoy, H. Alter, and A. S. Fauci. 1987. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J. Immunol. 138: 1064-1067.
7. Nag, P., J. Kim, V. Sapiega, A. L. Landay, J. W. Bremer, J. Mestecky, P. Reichelderfer, A. Kovacs, J. Cohn, B. Weiser, and L. L. Baum. 2004. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect. Dis. 190: 1970-1978.
8. Forthal, D. N., G. Landucci, and E. S. Daar. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75: 6953-6961.
9. Ahmad, R., S. T. Sindhu, E. Toma, R. Morisset, J. Vincelette, J. Menezes, and A. Ahmad. 2001. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21: 227-233.
10. Ljunggren, K., F. Chiodi, G. Biberfeld, E. Norrby, M. Jondal, and E. M. Fenyo. 1988. Lack of cross-reaction in antibody-dependent cellular cytotoxicity between human immunodeficiency virus (HIV) and HIV-related West African strains. J. Immunol. 140: 602-605.
11. Gomez-Roman, V. R., R. H. Florese, L. J. Patterson, B. Peng, D. Venzon, K. Aldrich, and M. Robert-Guroff. 2006. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308: 53-67.
12. Gomez-Roman, V. R., L. J. Patterson, D. Venzon, D. Liewehr, K. Aldrich, R. Florese, and M. Robert-Guroff. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174: 2185-2189.
13. Forthal, D. N., G. Landucci, T. B. Phan, and J. Becerra. 2005. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J. Virol. 79: 2042-2049.
14. Forthal, D. N., P. B. Gilbert, G. Landucci, and T. Phan. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178: 6596-6603.
15. Forthal, D. N., G. Landucci, K. S. Cole, M. Marthas, J. C. Becerra, and K. Van Rompay. 2006. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 80: 9217-9225.
16. Stratov, I., A. Chung, and S. J. Kent. 2008. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIVinfected subjects. J. Virol. 82: 5450-5459.
17. Center, R. J., P. L. Earl, J. Lebowitz, P. Schuck, and B. Moss. 2000. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J. Virol. 74: 4448-4455.
18. + T cells: implications for HIV vaccine strategies. J. Immunol. 179: 4571-4579.
19. Laakso, M. M., F. H. Lee, B. Haggarty, C. Agrawal, K. M. Nolan, M. Biscone, J. Romano, A. P. Jordan, G. J. Leslie, E. G. Meissner, et al. 2007. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 3: E117.
20. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178: 2746-2754.
21. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-2485.
22. + T cells. PLoS Med. 5: E100.
23. Fauci, A. S., D. Mavilio, and S. Kottilil. 2005. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5: 835-843.
24. + natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. USA 102: 2886-2891.
25. Kottilil, S., K. Shin, J. O. Jackson, K. N. Reitano, M. A. O'Shea, J. Yang, C. W. Hallahan, R. Lempicki, J. Arthos, and A. S. Fauci. 2006. Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J. Immunol. 176: 1107-1114.
26. Mavilio, D., G. Lombardo, A. Kinter, M. Fogli, A. La Sala, S. Ortolano, A. Farschi, D. Follmann, R. Gregg, C. Kovacs, et al. 2006. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 203: 2339-2350.
27. Martin, M. P., X. Gao, J. H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31: 429-434.
28. Martin, M. P., Y. Qi, X. Gao, E. Yamada, J. N. Martin, F. Pereyra, S. Colombo, E. E. Brown, W. L. Shupert, J. Phair, et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39: 733-740.
29. Alter, G., M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, et al. 2007. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204: 3027-3036.
30. Altfeld, M., and T. M. Allen. 2006. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol. 27: 504-510.
31. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13: 46-53.
32. Peut, V., and S. J. Kent. 2007. Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen. J. Virol. 81: 13125-13134.